, the UK-based clinical AI technology company, announced on Wednesday that it had inked a two-year agreement with global pharmaceutical firm Bayer to develop new treatments targeting cardiovascular disease.
The deal is expected to generate revenues of £5 million across the two years, with NHS trusts, a partner of Sensyne, to receive a 4% share of revenues from the collaboration.
The two companies will work together utilising Sensyne’s AI technology platform to accelerate clinical developments for new treatments targeting cardiovascular disease, a condition the NHS identified as a “clinical priority” in its Long Term Plan published at the start of 2019.
One core focus cited within the NHS’s plan is to improve outcomes across major diseases and the collaboration clearly supports this goal -- heart disease is reported to affect around 7 million people in the UK alone, accounting for one in four premature deaths.
Lord Paul Drayson, CEO of Sensyne Health, commented: "We are delighted to announce this new agreement with Bayer, which aims to accelerate the clinical development of new treatments for cardiovascular disease, a clinical priority for the NHS, using Sensyne Health's proprietary clinical AI technology platform."
Shares perked up almost 7% following this morning’s news.
The collaboration also marks a significant move to address an area which has received little investment over the last twenty years, the company explained, and it seems the use of artficial intelligence to address an area that has seen little innovation will be a valuable asset in driving forward drug discovery here.
Alongside this, real world evidence collected from Sensyne’s AI analysis of anonymised patient data corroborates the credibility of the platform to drive forward patient outcomes and drug discovery.
Additionally, Sensyne has underlined that they are working within a “ethical framework and business model”, with the NHS remaining the sole controller of patient data, eliminating the sale or transfer of data to a third party. The company will act as a ‘docking station’ for the analysis of anonymised patient data on behalf of commercial partners under strict ethical control.
For more News and Updates on Sensyne Health:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Eco (Atlantic) Oil & Gas (ECO) has released their results for Q2 2019 which featured a major oil discovery on its Orinduik license in Guyana and solid financials, including over £21 million in cash and cash equivalents.
SP Angel research note on commodities and miners, featuring: Bluejay Mining (JAY LN) 7.3p, Mkt cap £63m – Hudson’s White Mountain Anorthosite mine starts production this week in Greenland Hudson Resources (HUD CN) C$0.38/s, Mkt cap 68m Hummingbird Resources (HUM LN) 22.0p, Mkt Cap £77.8m – Interim results Katoro Gold (KAT LN) – Disposing of its Tanzanian gold projects Prospect Resources (PSC AU) – Power supply agreement for Arcadia
America’s biggest toymaker is to buy London-listed Entertainment One, A US House of Representatives committee has asked e-cigarette manufacturers to hand over details about the health impact of products, heaping renewed scrutiny on the popular devices
More waste could be sent to landfill in the UK after a no-deal Brexit, a major waste company has said. There are worries a no-deal outcome will disrupt the export of millions of tonnes of waste to facilities in the EU, so it will have to go to landfill.
The program was first launched in Mexico City in 2008 - using Symphony's plastic technology, Mexican-based Grupo Bimbo, the largest global baking company, tackles waste management with a clear mission: to make all packaging recyclable, biodegradable or compostable by 2025.
Predator Oil & Gas provide a progress update on its CO2 EOR project in Trinidad. Galileo Resources discuss the final technical report and inferred mineral resource estimate for its Star Zinc Project. Chris Bailey covers Rank Group, Antofagasta & CRH Plc
SP Angel research note on commodities and miners, featuring: Altus Strategies* (ALS LN) 4.8p, Mkt Cap £8.5m – Proposed JV on Lakanfla and Tabakorole in Mali Anglo Asian Mining* (AAZ LN) 149.5p, Mkt Cap £171m – Comment regarding media article Ariana Resources (AAU LN) 2.175p, Mkt Cap £23.0m –Salinbas drilling and licence update Aston Bay Holdings* (BAY CN) $0.065, Mkt cap C$7.6m – Soil sampling underway at Buckingham Gold project in Virginia, USA KEFI Minerals* (KEFI LN) 1.0p, Mkt Cap £7.0m – Appointment of NED Rambler Metals & Mining* (RMM LN) 0.075p, mkt cap £12.3m – Lombard Odier convertible loan closes
Chairman Dr. Clifford Gross believes such growth was attained through the company’s “unique approach of acquiring and commercialising university IP innovations, coupled with providing a range of IP services continues to deliver strong returns on invested capital.”